Leukemia-associated myeloid cells support distinct T-ALL subtypes via unique signals converging on metabolic alterations.

Leukemia-associated myeloid cells support multiple T-ALL subtypes through distinct signals that converge on metabolic reprogramming, with AKT activation being essential for survival.

• Why it matters: Understanding how myeloid cells support different T-ALL subtypes can reveal new therapeutic targets, especially since current treatments have significant toxicities and relapse issues.
• What they did: The study used transcriptional profiling and functional assays on mouse and human T-ALL models to show that myeloid cells promote survival via IL6ST/STAT3 signaling in ETP-like T-ALL and growth factor receptor pathways in non-ETP-like T-ALL, all requiring AKT activation.
• The result: Targeting myeloid support and oxidative phosphorylation together reduces T-ALL cell survival and extends survival in mouse models, highlighting combined metabolic and immune interactions as promising therapeutic strategies.